Clinical Trial Update: Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update of once-daily hydrocodone bitartrate tablets in chronic nonmalignant and nonneuropathic pain with a 24-week extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmalignant Pain
• Nonneuropathic Pain

Drugs mentioned

• Hydrocodone Bitartrate Tablets (hydrocodone bitartrate)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Chronic Nonmalignant and Nonneuropathic Pain | Phase 3 | Status: COMPLETED | Results posted: 2014-12-04